Teva will stop its Phase 2 emrusolmin study after an interim review found a low chance of meeting its main goal. No safety concerns were found, and Teva says this decision applies only to this study, but the weak result still weighs more heavily.
The finding weakens the case that emrusolmin can help adults with this condition. No safety problems were found, and Teva says this decision applies only to this study. Teva plans to review these results alongside data from an open-label extension before sharing its findings. That leaves the wider program open, but does not change the poor chance of meeting this study's goal.
Teva says Aurinia's U.S. patents are valid and enforceable, and its generic cannot launch before Dec. 7, 2036, unless defined conditions occur. That delay protects Aurinia from this generic competition, supporting its outlook.
Follow Teva Pharmaceuticals (TEVA) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for TEVA